Showing results (61-70 of 84) with videos related to

Sort By:
Pageof 9
Cancer Chemotherapy and Pharmacology|May 20, 2017
Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairmentGhassan K Abou-Alfa, Lionel D Lewis, Patricia LoRusso, et al.
Nucleic Acids Research|November 18, 2011
Structural analysis of an eIF3 subcomplex reveals conserved interactions required for a stable and proper translation pre-initiation complex assemblyAnna Herrmannová, Dalia Daujotyte, Ji-Chun Yang, et al.
Nucleic Acids Research|October 6, 2017
Embraced by eIF3: structural and functional insights into the roles of eIF3 across the translation cycleLeoš Shivaya Valášek, Jakub Zeman, Susan Wagner, et al.
Cancer Research|August 23, 2014
AEG-1 promoter-mediated imaging of prostate cancerAkrita Bhatnagar, Yuchuan Wang, Ronnie C Mease, et al.
BMC Genomics|May 5, 2023
Gene expression of male pathway genes sox9 and amh during early sex differentiation in a reptile departs from the classical amniote modelSusan Wagner, Sarah L Whiteley, Meghan Castelli, et al.
Elife|November 4, 2024
Perturbations in eIF3 subunit stoichiometry alter expression of ribosomal proteins and key components of the MAPK signaling pathwaysAnna Herrmannová, Jan Jelínek, Klára Pospíšilová, et al.
Molecular Cell|June 27, 2020
Selective Translation Complex Profiling Reveals Staged Initiation and Co-translational Assembly of Initiation Factor ComplexesSusan Wagner, Anna Herrmannová, Vladislava Hronová, et al.
The Plant Cell|June 13, 2006
Analysis of the Arabidopsis rsr4-1/pdx1-3 mutant reveals the critical function of the PDX1 protein family in metabolism, development, and vitamin B6 biosynthesisSusan Wagner, Anne Bernhardt, Jan Erik Leuendorf, et al.
PNAS Nexus|June 12, 2026
Active and probe-free intracellular rheology via phase-sensitive thermoviscous flowsIliya D Stoev, Madison Bolger-Munro, Antonio Minopoli, et al.
The Lancet. Oncology|February 26, 2018
Adjuvant vemurafenib in resected, BRAF<sup>V600</sup> mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trialMichele Maio, Karl Lewis, Lev Demidov, et al.
Pageof 9